vedolizumab,ustekinumab
takeda,janssen
['vedolizumab', 'vedo', 'crohn', 'ustekinumab']
biologic-naive patients treated with #vedolizumab and #ustekinumab for #crohns disease had similar rates of clinical response and remission, although mucosal healing and biologic treatment persistence differed at 36 months. #ddw23 
The content you need, when you need it.